Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Clancy, K. Mruk, K. Archer, M. Woelfel, J. Mongkolsapaya, G. Screaton, M. Lenardo, F. Chan (2005)
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.Proceedings of the National Academy of Sciences of the United States of America, 102 50
D. Siegmund, Stefanie Klose, Dong-hui Zhou, B. Baumann, C. Röder, H. Kalthoff, H. Wajant, A. Trauzold (2007)
Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.Cellular signalling, 19 6
R. Siegel, J. Muppidi, M. Sarker, A. Lobito, M. Jen, David Martin, S. Straus, M. Lenardo (2004)
SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane.The Journal of cell biology, 167 4
J. Medema, J. Jong, T. Hall, C. Melief, R. Offringa (1999)
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory ProteinThe Journal of Experimental Medicine, 190
L. Haswell, M. Glennie, A. Al-Shamkhani (2001)
Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154European Journal of Immunology, 31
B. Shen, T. Hage, W. Sebald (1996)
Global and Local Determinants for the Kinetics of Interleukin‐4/Interleukin‐4 Receptor α Chain InteractionFEBS Journal, 240
R. Kelley, K. Totpal, Stephanie Lindstrom, M. Mathieu, K. Billeci, L. Deforge, R. Pai, S. Hymowitz, A. Ashkenazi (2005)
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling*Journal of Biological Chemistry, 280
F. Henkler, E. Behrle, K. Dennehy, A. Wicovsky, N. Peters, C. Warnke, K. Pfizenmaier, H. Wajant (2005)
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stabilityThe Journal of Cell Biology, 168
Takashi Suda, Masato Tanaka, Masato Tanaka, Keiko Miwa, Shigekazu Nagata (1996)
Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand.Journal of immunology, 157 9
B. Shen, T. Hage, W. Sebald (1996)
Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein.European journal of biochemistry, 240 1
J. Bodmer, P. Schneider, J. Tschopp (2002)
The molecular architecture of the TNF superfamily.Trends in biochemical sciences, 27 1
P. Schneider, N. Holler, J. Bodmer, M. Hahne, K. Frei, A. Fontana, J. Tschopp (1998)
Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver ToxicityThe Journal of Experimental Medicine, 187
H. Wajant, D. Moosmayer, Thomas Wüest, Till Bartke, E. Gerlach, U. Schönherr, N. Peters, P. Scheurich, K. Pfizenmaier (2001)
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivativeOncogene, 20
N. Holler, A. Tardivel, M. Kovacsovics-Bankowski, S. Hertig, O. Gaide, F. Martinon, A. Tinel, D. Deperthes, S. Calderara, T. Schulthess, J. Engel, P. Schneider, J. Tschopp (2003)
Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling ComplexMolecular and Cellular Biology, 23
P. Schneider, J. Bodmer, N. Holler, C. Mattmann, Patricia Scuderi, A. Terskikh, M. Peitsch, J. Tschopp (1997)
Characterization of Fas (Apo-1, CD95)-Fas Ligand Interaction*The Journal of Biological Chemistry, 272
D. Merino, N. Lalaoui, Alexandre Morizot, P. Schneider, E. Solary, O. Micheau (2006)
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2Molecular and Cellular Biology, 26
Frank Mühlenbeck, P. Schneider, J. Bodmer, R. Schwenzer, Angelika Hauser, Gisela Schubert, P. Scheurich, D. Moosmayer, J. Tschopp, H. Wajant (2000)
The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation*The Journal of Biological Chemistry, 275
P. Schneider, D. Olson, A. Tardivel, B. Browning, A. Lugovskoy, Dahai Gong, M. Dobles, S. Hertig, K. Hofmann, H. Vlijmen, Y. Hsu, L. Burkly, J. Tschopp, T. Zheng (2003)
Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)*The Journal of Biological Chemistry, 278
M. Grell, E. Douni, H. Wajant, Matthias Löhden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, P. Scheurich (1995)
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptorCell, 83
P. Schneider, M. Thome, K. Burns, J. Bodmer, K. Hofmann, T. Kataoka, N. Holler, J. Tschopp (1997)
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.Immunity, 7 6
S. Mundle, A. Raza (2002)
Defining the dynamics of self-assembled Fas-receptor activation.Trends in immunology, 23 4
Gen Wu, T. Burns, Yi Zhan, E. Alnemri, W. El-Deiry (1999)
Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.Cancer research, 59 12
R. Kammerer, T. Schulthess, R. Landwehr, A. Lustig, D. Fischer, J. Engel (1998)
Tenascin-C Hexabrachion Assembly Is a Sequential Two-step Process Initiated by Coiled-coil α-Helices*The Journal of Biological Chemistry, 273
Geoffrey Stone, Suzanne Barzee, Victoria Snarsky, K. Kee, C. Spina, Xiao-Fang Yu, R. Kornbluth (2006)
Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA VaccinesJournal of Virology, 80
R. Locksley, N. Killeen, M. Lenardo (2001)
The TNF and TNF Receptor Superfamilies Integrating Mammalian BiologyCell, 104
Variants of human TRAIL (hTRAIL) and human CD95L (hCD95L), encompassing the TNF homology domain (THD), interact with the corresponding receptors and stimulate CD95 and TRAILR2 signaling after cross-linking. The murine counterparts (mTRAIL, mCD95L) showed no or only low receptor binding and were inactive/poorly active after cross-linking. The stalk region preceding the THD of mCD95L conferred secondary aggregation and restored CD95 activation in the absence of cross-linking. A corresponding variant of mTRAIL, however, was still not able to activate TRAIL death receptors, but gained good activity after cross-linking. Notably, disulfide-bonded fusion proteins of the THD of mTRAIL and mCD95L with a subdomain of the tenascin-C (TNC) oligomerization domain, which still assembled into trimers, efficiently interacted with their cognate cellular receptors and robustly stimulated CD95 and TRAILR2 signaling after secondary cross-linking. Introduction of the TNC domain also further enhanced the activity of THD encompassing variants of hTRAIL and hCD95L. Thus, spatial fixation of the N-terminus of the THD appears necessary in some TNF ligands to ensure proper receptor binding. This points to yet unanticipated functions of the stalk and/or transmembrane region of TNF ligands for the functionality of these molecules and offers a broadly applicable option to generate recombinant soluble ligands of the TNF family with superior activity.
Cell Death & Differentiation – Springer Journals
Published: Aug 17, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.